TY - JOUR T1 - Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e241 LP - e241 DO - 10.1136/annrheumdis-2020-218957 VL - 81 IS - 12 AU - Florence Jeny AU - Raphael Lhote AU - Gwenael Lorillon AU - Nicolas Belhomme AU - Grégory Pugnet AU - Raphaël Borie AU - Aurélien Justet AU - Stephane Jouneau AU - Nathalie Freymond AU - Arsène Mekinian AU - Robin Dhote AU - Yacine Tandjaoui-Lambiotte AU - Nathalie Saindenberg AU - Pierre Gazengel AU - Baptiste Hervier AU - Julien Haroche AU - Alexis Mathian AU - Miguel Hié AU - Thibaud Chazal AU - Dov Taieb AU - Yurdagul Uzunhan AU - Jérôme Le Pavec AU - Isabella Annesi-Maesano AU - Emmanuel Bergot AU - Abdellatif Tazi AU - Zahir Amoura AU - Dominique Valeyre AU - Hilario Nunes AU - Fleur Cohen-Aubart Y1 - 2022/12/01 UR - http://ard.bmj.com/content/81/12/e241.abstract N2 - Patients with interstitial lung disease have been considered at high risk of complications of COVID-19 because of their underlying lung disease and use of immunosuppressive agents.1 However, data on COVID-19 in patients with sarcoidosis are scarce.2–4 Several reasons for an increased risk of severe forms of COVID-19 among sarcoidosis patients have been hypothesised: the involvement of the lung in almost 90% of patients with COVID-19, some of whom have reduced pulmonary function and comorbidities such as diabetes or hypertension, which are largely associated with the use of glucocorticosteroids for treating sarcoidosis; and the use of immunosuppressive agents in a subset of these patients.5 Recently, Gyorfi et al 6 described the case of a patient with sarcoidosis who experienced a symptomatic SARS-CoV-2 infection with spontaneous clinical improvement, and a virological relapse after steroids treatment. This case illustrated the fact that immunosuppression with glucocorticoids may induce relapse of COVID-19 in patients with sarcoidosis. However, we lack data on the outcomes of patients with sarcoidosis affected by COVID-19. We retrospectively collected data for all patients with sarcoidosis and SARS-CoV-2 infection seen among 15 French centres between 1 March and 20 May 2020. The inclusion criteria were a sarcoidosis diagnosis based on the American Thoracic Society/European Respiratory Society/World Association for Sarcoidosis and other granulomatous … ER -